Reports Q4 revenue $22.66M, consensus $24.19M. "2022 was another year of remarkable execution for Apellis as we moved closer toward our goal of bringing SYFOVRE to patients with GA worldwide and continued to elevate the standard of care in PNH with EMPAVELI. Last week, we were thrilled to announce the FDA approval of SYFOVRE as the first and only treatment approved for patients living with GA, and we are now ready to launch in the U.S.," said Cedric Francois, co-founder and chief executive officer of Apellis. "With two commercial products, a robust pipeline of multiple late-stage programs, and a portfolio of pre-clinical assets heading towards the clinic, we believe we are in a strong position for 2023 and beyond."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Stifel biopharmaceuticals analyst to hold an analyst/industry conference call
- H.C. Wainwright says Belite Bio opportunity intact despite GA treatment approval
- Apellis price target raised to $115 from $79 at BofA